Regulatory information

The Royal Marsden is recognised nationally and internationally for excellence in cancer diagnosis, treatment, patient care and research.  

We are proud of the work we do and proud that other people think we do great work too. Here are some results from studies undertaken by the Care Quality Commission, the National Patient Safety Agency and others. You may also be interested in our promise to you.

The Royal Marsden holds a licence from the Human Tissue Authority (HTA) for the use of stem cells as part of the blood and bone marrow transplant programme, having successfully demonstrated that these tissues are used safely and ethically and with proper consent.

The HTA looks after the interests of the public by regulating organisations that remove, store and use human tissue for medical treatment. They also approve stem cell donations from donors who are unable to give consent.

The Royal Marsden received its first HTA licence in 2008. Inspections take place every two years, so that the HTA can satisfy themselves that the Trust continues to meet the required standards. The Royal Marsden's blood and marrow transplantation stem cell transplant laboratory was last inspected in 2014 and was found to be fully compliant.